• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    5.915 -0.195 (-3.19%)
    Streaming Delayed Price Updated: 11:55 AM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
    Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.